Given the longer clinical use of ranibizumab and aflibercept, a comparison of these two anti-VEGF drugs reveals that ranibizumab has significantly more cardiac disorders, neoplasms benign malignant and unspecified incl cysts and polyps, whereas aflibercept seems to have more injury poisoning and procedural complications, gastrointestinal disorders, surgical and medical procedures, and social circumstances. This evidence concerns the gene VEGFA and digestive system disorder.